INSMED | POWERED BY PURPOSECULTUREPATIENTSSCIENCEABOUTINVESTORSMISSION

& VISION

Insmed is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. We are powered by purpose, with an active promise to join your fight. BOARD OF DIRECTORS AT INSMED Steinar J. Engelsen, M.D. Director. Dr. Engelsen has been a member of our board since our inception in November 1999 and was a director of Insmed Pharmaceuticals, our predecessor entity, from 1998 to 2000. Since 1996, Dr. Engelsen has been a partner of Teknoinvest AS,

SARA M. BONSTEIN

Sara joined Insmed in January 2020, bringing more than 15 years of operational and financial leadership in the life sciences industry. Sara has extensive experience leading public biotech companies as CFO. Prior to joining Insmed, she served as the Chief Financial Officer, Chief Operating Officer, and Corporate Secretary at OncoSec Medical

and as the Chief

INVESTOR RELATIONS

Insmed (Nasdaq:INSM) is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Our strong and experienced management team embodies our culture, setting the tone for an organization that acts boldly, thinks creatively, and puts patients first in everything we do.

SEC FILINGS

Description. Date. Format. S-8. Securities offered to employees pursuant to employee benefit plans. May 19, 2021. Open Securities offered to employees pursuant to employee benefit plans in HTML. Open Securities offered to employees pursuant to employee benefit plans in DOC file. Open Securities offered to employees pursuant to employee

benefit

CAREERS AT INSMED

Careers. At Insmed, our dedication to patients is not just a company tagline. It’s an active promise to join their fight—to take a stand to pursue unmet needs and to work quickly and creatively to deliver meaningful results. See Our Available Opportunities. INSMED ANNOUNCES TOPLINE RESULTS FROM PHASE 1 STUDY OF BRIDGEWATER, N.J., Feb. 19, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced topline results from the Phase 1 study of treprostinil palmitil inhalation powder (TPIP) in healthy volunteers. Data from the study demonstrated that TPIP was generally safe INSMED INITIATES FRONTLINE CLINICAL TRIAL PROGRAM FOR BRIDGEWATER, N.J., Jan. 4, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that the first patient was dosed in late December, 2020, in the frontline clinical trial program of ARIKAYCE ® (amikacin liposome inhalation suspension) in patients with INSMED CALL FOR MEDICAL EDUCATION GRANT APPLICATIONS … MED-00477 Insmed is committed to improving the lives of patients with serious rare lung diseases through funding independent education programs that advance clinical knowledge, competence, and performance among healthcare providers. INSMED ANNOUNCES MANAGEMENT CHANGES Insmed Announces Management Changes. BRIDGEWATER, N.J., March 27, 2019 / PRNewswire / -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that Paolo Tombesi, Chief Financial Officer, will be leaving the company

effective June 2

INSMED | POWERED BY PURPOSECULTUREPATIENTSSCIENCEABOUTINVESTORSMISSION

& VISION

Insmed is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. We are powered by purpose, with an active promise to join your fight. BOARD OF DIRECTORS AT INSMED Steinar J. Engelsen, M.D. Director. Dr. Engelsen has been a member of our board since our inception in November 1999 and was a director of Insmed Pharmaceuticals, our predecessor entity, from 1998 to 2000. Since 1996, Dr. Engelsen has been a partner of Teknoinvest AS,

SARA M. BONSTEIN

Sara joined Insmed in January 2020, bringing more than 15 years of operational and financial leadership in the life sciences industry. Sara has extensive experience leading public biotech companies as CFO. Prior to joining Insmed, she served as the Chief Financial Officer, Chief Operating Officer, and Corporate Secretary at OncoSec Medical

and as the Chief

INVESTOR RELATIONS

Insmed (Nasdaq:INSM) is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Our strong and experienced management team embodies our culture, setting the tone for an organization that acts boldly, thinks creatively, and puts patients first in everything we do.

SEC FILINGS

Description. Date. Format. S-8. Securities offered to employees pursuant to employee benefit plans. May 19, 2021. Open Securities offered to employees pursuant to employee benefit plans in HTML. Open Securities offered to employees pursuant to employee benefit plans in DOC file. Open Securities offered to employees pursuant to employee

benefit

CAREERS AT INSMED

Careers. At Insmed, our dedication to patients is not just a company tagline. It’s an active promise to join their fight—to take a stand to pursue unmet needs and to work quickly and creatively to deliver meaningful results. See Our Available Opportunities. INSMED ANNOUNCES TOPLINE RESULTS FROM PHASE 1 STUDY OF BRIDGEWATER, N.J., Feb. 19, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced topline results from the Phase 1 study of treprostinil palmitil inhalation powder (TPIP) in healthy volunteers. Data from the study demonstrated that TPIP was generally safe INSMED INITIATES FRONTLINE CLINICAL TRIAL PROGRAM FOR BRIDGEWATER, N.J., Jan. 4, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that the first patient was dosed in late December, 2020, in the frontline clinical trial program of ARIKAYCE ® (amikacin liposome inhalation suspension) in patients with INSMED CALL FOR MEDICAL EDUCATION GRANT APPLICATIONS … MED-00477 Insmed is committed to improving the lives of patients with serious rare lung diseases through funding independent education programs that advance clinical knowledge, competence, and performance among healthcare providers. INSMED ANNOUNCES MANAGEMENT CHANGES Insmed Announces Management Changes. BRIDGEWATER, N.J., March 27, 2019 / PRNewswire / -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that Paolo Tombesi, Chief Financial Officer, will be leaving the company

effective June 2

ABOUT - INSMED

Insmed is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed employees work with a profound sense of urgency to deliver technologies and medicines in therapeutic areas with the greatest potential to make a difference in patients’ lives. At Insmed, the needs of patients

CONTACT INSMED

700 US Highway 202/206 Bridgewater, NJ 08807 Phone: (908) 977-9900. GPS: 700 US 206 Bridgewater Township, NJ 08807 PIPELINE AND DISEASES Insmed is advancing a pipeline to bring potential new treatments to patients with rare and serious diseases who currently have few, if any, treatment options. We are working with a profound sense of urgency to deliver creative applications of science and technology that have the potential to address these unmet needs.

ARIKAYCE® - INSMED

ARIKAYCE® (amikacin liposome inhalation suspension) is the first and only medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients who have limited or no alternative treatment options.

NEWS RELEASES

Apr 22, 2021. Insmed to Host First Quarter 2021 Financial Results Conference Call on Thursday, May 6, 2021. Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its first Apr 7, 2021.

NEWS RELEASES

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced positive data through six treatment cycles (72 weeks total duration) of its Phase 2 clinical trial program for INSMED ANNOUNCES PROPOSED CONCURRENT PUBLIC OFFERINGS OF BRIDGEWATER, N.J., May 10, 2021 /PRNewswire/ — Insmed Incorporated (Nasdaq: INSM) announced today that it intends to offer and sell $250 million of its common stock (the "Shares") and $500 million aggregate principal amount of its convertible senior notes due 2028 (the "Notes") in separate concurrent underwritten public offerings, a portion of which will be used to repurchase Insmed's INSMED ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 2 BRIDGEWATER, N.J., Feb. 3, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced positive top-line results from its global, randomized, double-blind placebo-controlled Phase 2 WILLOW study evaluating the efficacy, safety, and pharmacokinetics of INS1007 INSMED CALL FOR MEDICAL EDUCATION GRANT APPLICATIONS … MED-00477 Insmed is committed to improving the lives of patients with serious rare lung diseases through funding independent education programs that advance clinical knowledge, competence, and performance among healthcare providers. WILLIAM H. LEWIS, J.D., M.B.A. Insmed. About / Management Team / William H. Lewis, J.D., M.B.A. William H. Lewis, J.D., M.B.A. Chair and Chief Executive Officer. Will joined Insmed in 2012 as President and Chief Executive Officer and as a member of the board of directors. He became chair of the board of directors in November 2018. Will is the former Co-Founder, President INSMED | POWERED BY PURPOSECULTUREPATIENTSSCIENCEABOUTINVESTORSMISSION

& VISION

Insmed is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. We are powered by purpose, with an active promise to join your fight.

CONTACT INSMED

700 US Highway 202/206 Bridgewater, NJ 08807 Phone: (908) 977-9900. GPS: 700 US 206 Bridgewater Township, NJ 08807

INVESTOR RELATIONS

Insmed (Nasdaq:INSM) is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Our strong and experienced management team embodies our culture, setting the tone for an organization that acts boldly, thinks creatively, and puts patients first in everything we do.

CAREERS AT INSMED

Careers. At Insmed, our dedication to patients is not just a company tagline. It’s an active promise to join their fight—to take a stand to pursue unmet needs and to work quickly and creatively to deliver meaningful results. See Our Available Opportunities. BOARD OF DIRECTORS AT INSMED Steinar J. Engelsen, M.D. Director. Dr. Engelsen has been a member of our board since our inception in November 1999 and was a director of Insmed Pharmaceuticals, our predecessor entity, from 1998 to 2000. Since 1996, Dr. Engelsen has been a partner of Teknoinvest AS,

ARIKAYCE® - INSMED

ARIKAYCE® (amikacin liposome inhalation suspension) is the first and only medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients who have limited or no alternative treatment options.

SARA M. BONSTEIN

Sara joined Insmed in January 2020, bringing more than 15 years of operational and financial leadership in the life sciences industry. Sara has extensive experience leading public biotech companies as CFO. Prior to joining Insmed, she served as the Chief Financial Officer, Chief Operating Officer, and Corporate Secretary at OncoSec Medical

and as the Chief

SEC FILINGS

Description. Date. Format. S-8. Securities offered to employees pursuant to employee benefit plans. May 19, 2021. Open Securities offered to employees pursuant to employee benefit plans in HTML. Open Securities offered to employees pursuant to employee benefit plans in DOC file. Open Securities offered to employees pursuant to employee

benefit

INSMED ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 2 BRIDGEWATER, N.J., Feb. 3, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced positive top-line results from its global, randomized, double-blind placebo-controlled Phase 2 WILLOW study evaluating the efficacy, safety, and pharmacokinetics of INS1007 INSMED COMPLETES SALE OF FOLLOW-ON BIOLOGICS PLATFORM TOINSMED CORPORATIONINSMED NEWSINSMED PHARMACEUTICALSINSMED PHARMAINSMED PHARMACEUTICALS INCINSMED PHARMACEUTICALS NEWS RICHMOND, Va., March 31, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Insmed Inc. (Nasdaq: INSM), a biopharmaceutical company, announced today that it has successfully closed the sale of all of the Company's assets related to its follow-on biologics business to a INSMED | POWERED BY PURPOSECULTUREPATIENTSSCIENCEABOUTINVESTORSMISSION

& VISION

Insmed is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. We are powered by purpose, with an active promise to join your fight.

CONTACT INSMED

700 US Highway 202/206 Bridgewater, NJ 08807 Phone: (908) 977-9900. GPS: 700 US 206 Bridgewater Township, NJ 08807

INVESTOR RELATIONS

Insmed (Nasdaq:INSM) is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Our strong and experienced management team embodies our culture, setting the tone for an organization that acts boldly, thinks creatively, and puts patients first in everything we do.

CAREERS AT INSMED

Careers. At Insmed, our dedication to patients is not just a company tagline. It’s an active promise to join their fight—to take a stand to pursue unmet needs and to work quickly and creatively to deliver meaningful results. See Our Available Opportunities. BOARD OF DIRECTORS AT INSMED Steinar J. Engelsen, M.D. Director. Dr. Engelsen has been a member of our board since our inception in November 1999 and was a director of Insmed Pharmaceuticals, our predecessor entity, from 1998 to 2000. Since 1996, Dr. Engelsen has been a partner of Teknoinvest AS,

ARIKAYCE® - INSMED

ARIKAYCE® (amikacin liposome inhalation suspension) is the first and only medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients who have limited or no alternative treatment options.

SARA M. BONSTEIN

Sara joined Insmed in January 2020, bringing more than 15 years of operational and financial leadership in the life sciences industry. Sara has extensive experience leading public biotech companies as CFO. Prior to joining Insmed, she served as the Chief Financial Officer, Chief Operating Officer, and Corporate Secretary at OncoSec Medical

and as the Chief

SEC FILINGS

Description. Date. Format. S-8. Securities offered to employees pursuant to employee benefit plans. May 19, 2021. Open Securities offered to employees pursuant to employee benefit plans in HTML. Open Securities offered to employees pursuant to employee benefit plans in DOC file. Open Securities offered to employees pursuant to employee

benefit

INSMED ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 2 BRIDGEWATER, N.J., Feb. 3, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced positive top-line results from its global, randomized, double-blind placebo-controlled Phase 2 WILLOW study evaluating the efficacy, safety, and pharmacokinetics of INS1007 INSMED COMPLETES SALE OF FOLLOW-ON BIOLOGICS PLATFORM TOINSMED CORPORATIONINSMED NEWSINSMED PHARMACEUTICALSINSMED PHARMAINSMED PHARMACEUTICALS INCINSMED PHARMACEUTICALS NEWS RICHMOND, Va., March 31, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Insmed Inc. (Nasdaq: INSM), a biopharmaceutical company, announced today that it has successfully closed the sale of all of the Company's assets related to its follow-on biologics business to a

PATIENTS - INSMED

patients. An active promise to join your fight. Our commitment to patients is not just a company tagline. It is an active promise to join your fight—to take a stand to pursue unmet needs and to work quickly and creatively to deliver meaningful results.

ABOUT - INSMED

Insmed is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed employees work with a profound sense of urgency to deliver technologies and medicines in therapeutic areas with the greatest potential to make a difference in patients’ lives. At Insmed, the needs of patients PIPELINE AND DISEASES Insmed is advancing a pipeline to bring potential new treatments to patients with rare and serious diseases who currently have few, if any, treatment options. We are working with a profound sense of urgency to deliver creative applications of science and technology that have the potential to address these unmet needs.

ARIKAYCE® - INSMED

ARIKAYCE® (amikacin liposome inhalation suspension) is the first and only medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients who have limited or no alternative treatment options. THE HISTORY OF INSMED Insmed History Wall. An installation at Insmed’s global headquarters honors the Company’s past as we look toward the future. From the early days of the two original companies that formed Insmed to the FDA approval and launch of our first therapy, the wall highlights some of the most significant moments in Insmed’s history and showcases the values that we live every day.

MANAGEMENT TEAM

Management Team. Insmed has built a strong management team with extensive biopharmaceutical experience and a proven track record in research, drug development, and commercialization. Our management team members embody our culture, setting the tone for an organization that acts boldly, thinks creatively, and puts patients first in everything

we do.

INSMED ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 2 BRIDGEWATER, N.J., Feb. 3, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced positive top-line results from its global, randomized, double-blind placebo-controlled Phase 2 WILLOW study evaluating the efficacy, safety, and pharmacokinetics of INS1007

STOCK INFORMATION

Stock Information. The interactive chart below shows a historical timeline of our stock price and trading volume. Click on the tabs below to view the different timeframes. You may also view data on Dividend, Split, and Earning History by using the Events tab. In this

section.

ROGER ADSETT

Roger joined Insmed in September of 2016 as Chief Commercial Officer, and in November 2019 was appointed Chief Operating Officer. Prior to Insmed, Roger held various leadership roles with Shire from 2005 to 2016. During his time as senior vice president of its gastrointestinal and internal medicine business unit, Roger oversaw global commercial

P&L across

INSMED CALL FOR MEDICAL EDUCATION GRANT APPLICATIONS … MED-00477 Insmed is committed to improving the lives of patients with serious rare lung diseases through funding independent education programs that advance clinical knowledge, competence, and performance among healthcare providers.

Close

* Skip to main content

* Skip to footer

Insmed

Your browser does not support the video tag.

culture

WE ARE POWERED BY PURPOSE. Your browser does not support the video tag.

patients

AN ACTIVE PROMISE TO JOIN YOUR FIGHT.

OUR COVID-19

RESPONSE.

Your browser does not support the video tag.

science

FINDING ANSWERS.

FOOTER

* Culture __

* Mission & Vision

* Careers

* Responsibility

* Patients __

* ARIKAYCE®

* Resources

* Science __

* Pipeline

* PULMOVANCE™ Liposomal Technology

* Diseases

* Clinical Trials

* Investigator-Initiated Research

* About __

* History

* Management Team

* Board of Directors * Global Healthcare Compliance

* Investors __

* Events & Presentations

* Stock Information

* News Releases

* SEC Filings

* Analyst Coverage

* Corporate Governance

* Email Alerts

* Investor FAQs

Contact Us

Insmed Incorporated © 2019 All rights reserved. Insmed Incorporated © 2019 All rights reserved. Insmed, ARIKAYCE, Arikares, and PULMOVANCE are trademarks of Insmed Incorporated. All other trademarks are property of their respective

owner.

Terms of Use Privacy Policy

Contact Us

* Culture __

__

* Mission & Vision

* Careers

* Responsibility

* Patients __

__

* ARIKAYCE®

* Resources

* Science __

__

* Pipeline

* PULMOVANCE™ Liposomal Technology

* Diseases

* Clinical Trials

* Investigator-Initiated Research

* About __

__

* History

* Management Team

* Board of Directors * Global Healthcare Compliance

* Investors __

__

* Events & Presentations

* Stock Information

* News Releases

* SEC Filings

* Analyst Coverage

* Corporate Governance

* Email Alerts

* Investor FAQs

Contact Us

� Insmed 2019. All Rights Reserved.Terms of Use

Privacy Policy

Effective January 1, 2020, we have modified our Privacy Policy . Please read these updated terms and take some time to understand them. This website, as well as certain third parties that provide content, other functionality, or services to this site, may use Internet technologies to collect information. These technologies include cookies, local stored objects, web beacons, and other means. By using this site, you consent to our use of such cookies and similar technologies .Ok